



Julian Mackenzie is a senior executive with a successful record in global healthcare organizations in top finance and general management positions.



Julian M. Mackenzie

CEO, Ascendx Spine™
An internationally successful executive in the spine business.

“We have great expectations,” says Mackenzie.

THE ASCENDX SPINE VCF REPAIR SYSTEM IS DESIGNED TO SET A NEW STANDARD OF CARE FOR TREATING VERTEBRAL COMPRESSION FRACTURE.

Julian Mackenzie *knows* the spine business, with nearly two decades of experience in the medical device industry. He was previously CEO of SpineVision from 2006 to 2009, during which time sales grew from 6.0 million Euros to 9.5 million Euros and operating losses decreased from 18 million Euros to 6 million Euros. He also raised 15 million Euros, fostered various exit strategies for the investors, rationalized the company's product offerings, and engaged distributors internationally. From 2000 to 2006 Mr. Mackenzie was Director General of Wright Medical Europe, when sales grew from 35 million Euros to over 60 million. Prior to 2000, he held various executive positions, including Director of Finance at Europe Boston Scientific.

ASCENDX SPINE'S VCF REPAIR SYSTEM IS A POTENTIALLY DISRUPTIVE TECHNOLOGY FOR THE TREATMENT OF VERTEBRAL COMPRESSION FRACTURE.

The **Ascendx VCF Repair System** is designed for the improved treatment of vertebral compression fractures (VCF) caused by osteoporosis, cancer or trauma. VCF forces a vertebra to collapse and the spinal column above it to assume an abnormal forward curve, resulting in considerable back pain and a hunchbacked appearance. The current standard procedures for treating VCF are 'vertebroplasty' and 'kyphoplasty.' While the Ascendx VCF Repair Systems accesses the vertebral body in a similar manner to the traditional therapies, the Ascendx system enables the *precise* placement of the cement while the balloon is still inflated at the site of the fracture. Ascendx is designed to be an advance over traditional therapies. Ascendx is less invasive and only requires a *single* incision and is designed to enable the physician to precisely place a uniform bolus of cement in the center of the vertebral body, thereby potentially reducing the occurrence of adjacent level fractures and cement leakage. The Company received CE mark registration in September 2011 and expects to receive FDA clearance in 2012. **A 60-patient, multicenter clinical trial in the U.S. has already been successfully completed, with follow-up conducted at 30 days, 3 months, 6 months and 12 months.**

Prior to being recruited to Ascendx Spine as Chief Executive Officer in June 2010, Mr. Mackenzie was CEO of SpineVision SA. Earlier in his career, he served as Director General and CFO of Wright Medical Europe SA. Previously, he was European Finance Director and European Mergers and Acquisitions Project Director for Boston Scientific Corporation. “The Ascendx VCF Repair System is designed to set a new standard of care over kyphoplasty for treating vertebral compression fractures.”